Incyte Corporation (INCY) Shares Sold by Ardsley Advisory Partners

Ardsley Advisory Partners reduced its holdings in Incyte Corporation (NASDAQ:INCY) by 28.6% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,500 shares of the biopharmaceutical company’s stock after selling 1,000 shares during the quarter. Ardsley Advisory Partners’ holdings in Incyte Corporation were worth $315,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Vanguard Group Inc. increased its holdings in Incyte Corporation by 11.1% in the second quarter. Vanguard Group Inc. now owns 17,125,542 shares of the biopharmaceutical company’s stock worth $2,156,276,000 after purchasing an additional 1,709,685 shares in the last quarter. State Street Corp increased its holdings in Incyte Corporation by 110.7% in the first quarter. State Street Corp now owns 7,581,684 shares of the biopharmaceutical company’s stock worth $1,013,437,000 after purchasing an additional 3,983,207 shares in the last quarter. Capital International Investors increased its holdings in Incyte Corporation by 4.0% in the second quarter. Capital International Investors now owns 6,407,197 shares of the biopharmaceutical company’s stock worth $806,730,000 after purchasing an additional 246,134 shares in the last quarter. BB Biotech AG increased its holdings in Incyte Corporation by 0.7% in the second quarter. BB Biotech AG now owns 3,514,822 shares of the biopharmaceutical company’s stock worth $442,551,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Matrix Capital Management Company LP increased its holdings in Incyte Corporation by 28.3% in the second quarter. Matrix Capital Management Company LP now owns 1,796,716 shares of the biopharmaceutical company’s stock worth $226,225,000 after purchasing an additional 396,716 shares in the last quarter. Institutional investors and hedge funds own 88.88% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Incyte Corporation (INCY) Shares Sold by Ardsley Advisory Partners” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://ledgergazette.com/2017/10/18/incyte-corporation-incy-shares-sold-by-ardsley-advisory-partners.html.

Incyte Corporation (NASDAQ:INCY) traded up 0.151% on Wednesday, reaching $115.815. The company’s stock had a trading volume of 583,189 shares. The stock’s market cap is $23.82 billion. Incyte Corporation has a 12-month low of $83.01 and a 12-month high of $153.15. The company’s 50 day moving average price is $120.02 and its 200-day moving average price is $126.06.

Incyte Corporation (NASDAQ:INCY) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.01). The business had revenue of $326.40 million during the quarter, compared to the consensus estimate of $318.45 million. Incyte Corporation had a negative return on equity of 21.57% and a negative net margin of 11.77%. The firm’s revenue for the quarter was up 32.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.18 EPS. On average, equities analysts expect that Incyte Corporation will post ($0.81) EPS for the current year.

A number of equities research analysts have weighed in on the company. Goldman Sachs Group, Inc. (The) assumed coverage on Incyte Corporation in a report on Friday, October 6th. They issued a “buy” rating and a $160.00 target price for the company. Jefferies Group LLC reiterated a “buy” rating on shares of Incyte Corporation in a report on Friday, October 6th. Royal Bank Of Canada assumed coverage on Incyte Corporation in a report on Thursday, September 14th. They issued a “sector perform” rating and a $136.00 target price for the company. Argus reiterated a “buy” rating and issued a $150.00 target price on shares of Incyte Corporation in a report on Wednesday, September 13th. Finally, Oppenheimer Holdings, Inc. reiterated a “hold” rating and issued a $135.00 target price on shares of Incyte Corporation in a report on Sunday, September 10th. Seven analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $144.84.

In other Incyte Corporation news, President Herve Hoppenot sold 70,502 shares of Incyte Corporation stock in a transaction on Monday, September 18th. The stock was sold at an average price of $119.45, for a total value of $8,421,463.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperli

A number of other hedge funds have also modified their holdings of the business. Vanguard Group Inc. increased its holdings in Incyte Corporation by 11.1% in the second quarter. Vanguard Group Inc. now owns 17,125,542 shares of the biopharmaceutical company’s stock worth $2,156,276,000 after purchasing an additional 1,709,685 shares in the last quarter. State Street Corp increased its holdings in Incyte Corporation by 110.7% in the first quarter. State Street Corp now owns 7,581,684 shares of the biopharmaceutical company’s stock worth $1,013,437,000 after purchasing an additional 3,983,207 shares in the last quarter. Capital International Investors increased its holdings in Incyte Corporation by 4.0% in the second quarter. Capital International Investors now owns 6,407,197 shares of the biopharmaceutical company’s stock worth $806,730,000 after purchasing an additional 246,134 shares in the last quarter. BB Biotech AG increased its holdings in Incyte Corporation by 0.7% in the second quarter. BB Biotech AG now owns 3,514,822 shares of the biopharmaceutical company’s stock worth $442,551,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Matrix Capital Management Company LP increased its holdings in Incyte Corporation by 28.3% in the second quarter. Matrix Capital Management Company LP now owns 1,796,716 shares of the biopharmaceutical company’s stock worth $226,225,000 after purchasing an additional 396,716 shares in the last quarter. Institutional investors and hedge funds own 88.88% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Incyte Corporation (INCY) Shares Sold by Ardsley Advisory Partners” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://ledgergazette.com/2017/10/18/incyte-corporation-incy-shares-sold-by-ardsley-advisory-partners.html.

Incyte Corporation (NASDAQ:INCY) traded up 0.151% on Wednesday, reaching $115.815. The company’s stock had a trading volume of 583,189 shares. The stock’s market cap is $23.82 billion. Incyte Corporation has a 12-month low of $83.01 and a 12-month high of $153.15. The company’s 50 day moving average price is $120.02 and its 200-day moving average price is $126.06.

Incyte Corporation (NASDAQ:INCY) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.01). The business had revenue of $326.40 million during the quarter, compared to the consensus estimate of $318.45 million. Incyte Corporation had a negative return on equity of 21.57% and a negative net margin of 11.77%. The firm’s revenue for the quarter was up 32.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.18 EPS. On average, equities analysts expect that Incyte Corporation will post ($0.81) EPS for the current year.

A number of equities research analysts have weighed in on the company. Goldman Sachs Group, Inc. (The) assumed coverage on Incyte Corporation in a report on Friday, October 6th. They issued a “buy” rating and a $160.00 target price for the company. Jefferies Group LLC reiterated a “buy” rating on shares of Incyte Corporation in a report on Friday, October 6th. Royal Bank Of Canada assumed coverage on Incyte Corporation in a report on Thursday, September 14th. They issued a “sector perform” rating and a $136.00 target price for the company. Argus reiterated a “buy” rating and issued a $150.00 target price on shares of Incyte Corporation in a report on Wednesday, September 13th. Finally, Oppenheimer Holdings, Inc. reiterated a “hold” rating and issued a $135.00 target price on shares of Incyte Corporation in a report on Sunday, September 10th. Seven analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $144.84.

In other Incyte Corporation news, President Herve Hoppenot sold 70,502 shares of Incyte Corporation stock in a transaction on Monday, September 18th. The stock was sold at an average price of $119.45, for a total value of $8,421,463.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Barry P. Flannelly sold 714 shares of Incyte Corporation stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $124.25, for a total value of $88,714.50. Following the completion of the sale, the executive vice president now directly owns 15,496 shares of the company’s stock, valued at approximately $1,925,378. The disclosure for this sale can be found here. In the last three months, insiders sold 109,452 shares of company stock valued at $13,707,134. Corporate insiders own 17.70% of the company’s stock.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Institutional Ownership by Quarter for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply